What I have: tirzepatide · SURPASS-2.
I can predict the outcome but I cannot explain it, which means I will get the next case wrong.
I would like to know how confident the field actually is about this.
So what is the mechanism, and how well established is it?
Read SURPASS-2 by arm, because the arm is the unit of randomisation and every figure worth quoting is defined at that level. A programme that randomised several dose levels reports each one separately, with its own sample size and its own interval, and the pooled number that circulates afterwards describes a group nobody was assigned to. Take the primary publication and its supplementary tables rather than a summary of them: one is organised by arm, the other by whichever figure was largest. And check the estimand — what happened to everyone assigned, or what happens to those who kept taking it — because the two answer different questions and are routinely quoted as though they were one.
The honest answer is that appetite suppression is centrally mediated and gastric emptying is peripheral, and the two contribute different amounts in different people.
Receptor density and downstream coupling differ between tissues, so the dose-response curves for glycaemia, weight and nausea are not the same curve. That is the pharmacological basis for titration.
The part that matters: gastric emptying delay attenuates with continued exposure for long-acting agents through receptor desensitisation, which is why the early nausea usually settles while the appetite effect persists.
The incretin effect itself was established by comparing the insulin response to oral and intravenous glucose loads matched for plasma glucose; the difference is what the gut hormones contribute.
Tissue distribution first, then signalling. Nearly every question in this tag resolves at the first step.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsThe endogenous hormone is degraded by dipeptidyl peptidase-4 within a couple of minutes. Every long-acting agent in this class is essentially an answer to that one problem.
Native GLP-1 has a circulating half-life of one to two minutes because dipeptidyl peptidase-4 cleaves the two N-terminal residues. Substituting the position-8 alanine, as the long-acting analogues do, blocks that cleavage and is the single most consequential modification in the class.
Albumin binding does the rest of the work. A fatty-acid chain attached through a linker binds circulating albumin reversibly, which both shields the peptide from renal clearance and creates a depot; that is how a two-minute hormone becomes a once-weekly drug.
The position-8 substitution conferring DPP-4 resistance appears in essentially every long-acting agent in the class, which is about as strong a piece of convergent evidence as medicinal chemistry offers.
The caveat is that mechanism predicts direction and rarely predicts magnitude in an individual, and people reason from mechanism to dose far too confidently.
The half-life problem and the albumin-binding solution are the whole story of the class chemically.
Answer first: the receptor is a class B G-protein-coupled receptor signalling mainly through Gs and cyclic AMP, and almost every downstream effect people ask about traces back to where that receptor is expressed rather than to what it does when activated.
Biased agonism — differential recruitment of beta-arrestin versus G-protein signalling — is an active research area and is one hypothesis for why agents with similar receptor affinity have different tolerability.
Stated carefully, glucagon suppression is also glucose-dependent and is lost during hypoglycaemia, which preserves the counter-regulatory response — a genuinely elegant piece of physiology and the reason the class is safe in this respect.
Structural work on the receptor by cryo-electron microscopy has resolved the agonist-bound active state and is the basis for current structure-guided design in this class.
Research-use material is not approved for human use, and mechanism is not a safety argument.
Glucose-dependence is the property to remember; it explains the safety profile on its own.
The receptor is also expressed in the heart, kidney and vasculature, which is the plausible route for effects that are not obviously metabolic.
Glucose-dependence arises because the insulinotropic signal amplifies glucose-stimulated secretion rather than initiating secretion. With no glucose signal to amplify, there is little to amplify.
Area postrema involvement in nausea from this class is supported by lesion studies in animals and by the anatomy of the circumventricular organs.
Mechanism is a good guide to what to expect and a poor guide to how much.
Answering this needs the distinction between the native hormone and the pharmacological agents, whose half-lives differ by three orders of magnitude and whose effects therefore differ in kind.
Central effects reach the arcuate nucleus and the area postrema, regions with an incomplete blood-brain barrier. That anatomy is why a large peptide can act centrally at all, and it also explains the nausea, since the area postrema is the chemoreceptor trigger zone.
The structural basis of semaglutide’s pharmacokinetics — Aib-8, the Arg34Lys substitution and the C18 diacid–AEEA linker at Lys26 — is described in the original medicinal chemistry publication, and it is worth reading once because it makes the design logic explicit[1].
A receptor being expressed in a tissue does not establish that activating it there matters at therapeutic exposures.
Nausea and appetite share an anatomy, which is why they are hard to separate by dose.
edited 22 Jun 2026 by tyndall_haze — removed a claim I could not source
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.